Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma
Authors:
- Hipolito Otoniel Miranda-RobleroHMHipolito Otoniel Miranda-Roblero
- Liliana Faridi Saavedra-SalazarLSLiliana Faridi Saavedra-Salazar
- Marina Galicia-MorenoMGMarina Galicia-Moreno
- Scarlet Arceo-OrozcoSAScarlet Arceo-Orozco
- Fernando Caloca-CamarenaFCFernando Caloca-Camarena
- Ana Sandoval-RodríguezASAna Sandoval-Rodríguez
- Jesús García-BañuelosJesús García-Bañuelos
- Claudia Frias-GonzalezCFClaudia Frias-Gonzalez
- Monica Almeida-LópezMAMonica Almeida-López
- Erika Martínez-LópezEMErika Martínez-López
- Juan Armendariz-BorundaJAJuan Armendariz-Borunda
- Hugo Christian Monroy-RamirezHMHugo Christian Monroy-Ramirez
Preprint
- 5 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Hepatocellular carcinoma (HCC) development is associated with altered modifications in DNA methylation, changing transcriptional regulation. Emerging evidence indicates that DNA methyltransferase 1 (DNMT1) plays a key role in carcinogenesis process. This study aimed to investigate how pirfenidone (PFD) modifies this pathway and the effect generated by the association between c-Myc expression and DNMT1 activation. Rats F344 were used for HCC development using 50 mg/kg of diethylnitrosamine (DEN) and 25 mg/kg of 2-aminofluorene (2-AAF). HCC/PFD group received simultaneous doses of 300 mg/kg of PFD. All treatments lasted 12 weeks. On the other hand, HepG2 cells were used to evaluate the effects of PFD in restoring DNA methylation in the presence of the inhibitor 5-Aza. Histopathological, biochemical, immunohistochemical, and western blot analysis were carried out and our findings showed that PFD treatment reduced the amount and size of tumors along with decreased Glipican-3, β-catenin, and c-Myc expression in nuclear fractions. Also, this treatment improved lipid metabolism by modulating PPARγ and SREBP1 signaling. Interestingly, PFD augmented DNMT1 and DNMT3a protein expression, which restores global methylation, both in our in vivo and in vitro models. In conclusion, our results suggest that PFD could slow down HCC development by controlling DNA methylation.Keywords
All Related Versions
- Version 1, 2024-04-05, Preprints
- Published version: Cells, 13 (12), 1013.
This publication has 41 references indexed in Scilit:
- Enrichment of progenitor cells by 2‐acetylaminofluorene accelerates liver carcinogenesis induced by diethylnitrosamine in vivoMolecular Carcinogenesis, 2021
- Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 lineAnnals of Hepatology, 2020
- Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cellsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2020
- Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPKHepatology Communications, 2020
- Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of CirrhosisJournal of Gastrointestinal Surgery, 2019
- Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinomaDigestive and Liver Disease, 2019
- Inhibitory Role of Peroxisome Proliferator-Activated Receptor Gamma in Hepatocarcinogenesis in Mice and in VitroHepatology, 2010
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinomaHepatology, 2008
- The Epigenomics of CancerCell, 2007